Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Induction of Specific Immune Responses Against Melanoma-Associated Antigens in Vivo by Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial

NCT00204607 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT00204607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00204607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Induction of Specific Immune Responses Against Melanoma-Associated Antigens in Vivo by Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial
Lead sponsor
University Hospital Tuebingen
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2004
Completion date
January 31, 2007
Enrollment
20
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malignant melanoma